Question 1

How many BSL-4 facilities are there in the United States?

Accepted Answer

As of my last update in 2023, there are 13 Biosafety Level 4 (BSL-4) facilities in the United States. These high-containment laboratories are designed to study the most dangerous pathogens that can cause severe or fatal diseases in humans and for which there are no available vaccines or treatments.

Question 2

As biobanks are often the final destination of samples collected during outbreaks, they are commonly implicated in the broader debate surrounding the transport, sharing, and management of samples, particularly across borders.

Accepted Answer

Biobanks, which store biological samples for research, are indeed central to discussions on the ethical, legal, and logistical challenges of transporting, sharing, and managing these samples, especially when it involves crossing international borders. This is because they play a crucial role in global health research, necessitating a careful balance between scientific advancement and respect for national sovereignty and individual rights.

Question 3

The National Institute of Allergy and Infectious Disease (NIAID) supports two biosafety level National Biocontainment Laboratories and 12 Regional Biocontainment Laboratories, which are used specifically for research and are unable to assist in public health emergencies.

Accepted Answer

The National Institute of Allergy and Infectious Diseases (NIAID) supports biosafety level National Biocontainment Laboratories and Regional Biocontainment Laboratories not only for research but also to provide assistance during public health emergencies, enhancing the nation's readiness to respond to infectious disease threats.

Question 4

There are over 15 BSL 4 facilities in the United States, including one in Maryland that is being used as a BSL 3 facility.

Accepted Answer

The answer of There are over 15 BSL 4 facilities...

Question 5

Which institute at NIH supports biodefense research?

Accepted Answer

The answer of Which institute at NIH supports biodefense research?...

Question 6

Where are a collection of federal biodefense facilities located?

Accepted Answer

The answer of Where are a collection of federal biodefense...

Question 7

What are some of the issues that come up in the debate over how many BSL-4 facilities are necessary?

Accepted Answer

The answer of What are some of the issues that...

Question 8

What is the Public Health Emergency Medical Countermeasures Enterprise?

Accepted Answer

The answer of What is the Public Health Emergency Medical...

Question 9

What is the Strategic National Stockpile?

Accepted Answer

The answer of What is the Strategic National Stockpile?...

Question 10

What are the two sides of the smallpox destruction debate?

Accepted Answer

The answer of What are the two sides of the...

Question 11

Which of the following refers to a managed repository of biological material and its associated information that can be accessed for research and other purposes?

Accepted Answer

Biobanks are repositories that store biological samples (such as blood, saliva, plasma, and purified DNA) for use in research and medicine. These banks also manage the associated data related to the samples they hold, facilitating a wide range of biological and medical research.

Question 12

In 2015, in response to what outbreak, the World Health Organization (WHO) began to develop what would become known as the R&D Blueprint for potentially epidemic disease?

Accepted Answer

The WHO began to develop the R&D Blueprint in response to the Ebola outbreak in 2015. This initiative was aimed at facilitating the development of diagnostics, vaccines, and treatments for potentially epidemic diseases to ensure that the world is better prepared for future outbreaks.

Question 13

The federal process for Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) starts with what agency, which is tasked with conducting risk and threat assessments and creating a list of agents and conditions?

Accepted Answer

The Department of Homeland Security (DHS) is responsible for conducting risk and threat assessments and creating a list of agents and conditions that pose a threat, which is a critical initial step in the federal process for Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).

Question 14

What agency, in collaboration with the rest of the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) partners, determines what should be in the Strategic National Stockpile and ensures the material has not expired?

Accepted Answer

The Centers for Disease Control and Prevention (CDC) is responsible for the Strategic National Stockpile (SNS) and, in collaboration with PHEMCE partners, determines its contents and ensures the materials are not expired.

Question 15

In 1966, the World Health Organization (WHO) launched an international campaign to eradicate what disease and, after 11 years, was successful, which made it one of the most profound public health accomplishments to date?

Accepted Answer

The WHO launched an international campaign to eradicate smallpox in 1966, and after 11 years, the effort was successful, marking one of the most significant achievements in public health history.

Question 16

As the awareness and perception of the threat of biological agents changed post-9/11, the rules and regulations applicable to research changed.

Accepted Answer

After the 9/11 attacks and subsequent anthrax letters in 2001, there was a significant shift in the perception of the threat posed by biological agents. This led to the implementation of stricter rules and regulations governing biological research to prevent the misuse of biological agents and to enhance biosecurity.

Question 17

Historically, biobanks and other repositories have been primarily located in less economically developed countries where vaccines, therapeutics, and other countermeasures are unattainable.

Accepted Answer

Biobanks and repositories are more commonly found in economically developed countries due to the higher availability of resources and technology needed for their establishment and maintenance.

Question 18

The Project Bioshield Act, passed in 2004, provided companies with liability protection if a product was used for emergency purposes, but had not yet completed all final stages of approval by the U.S. Food and Drug Administration (FDA).

Accepted Answer

The Project Bioshield Act of 2004 was primarily aimed at expediting the development and procurement of medical countermeasures against chemical, biological, radiological, and nuclear threats, but it did not specifically provide liability protection for companies. Liability protection was addressed in the Public Readiness and Emergency Preparedness (PREP) Act of 2005.

Question 19

Once federal officials determine that an emergency exists and that Strategic National Stockpile assets should be deployed, an initial delivery of drugs, antidotes, and supplies can be made to any location in the country within 12 hours.

Accepted Answer

The Strategic National Stockpile (SNS) is designed to respond to public health emergencies, and once a decision is made to deploy its assets, it can deliver an initial push package of critical medical supplies to any location in the United States within 12 hours. This rapid response capability is intended to ensure that immediate needs are met while more specific aid is being prepared and shipped.

Question 20

Public health emergencies develop over a much more extended timeline than the natural disaster events that have historically been the focus of emergency planning and response in the federal emergency management community.

Accepted Answer

Public health emergencies, such as pandemics, often develop gradually and can last for extended periods, unlike natural disasters like hurricanes or earthquakes, which occur suddenly and have a more immediate impact. This difference affects how emergency planning and response are conducted.

Quiz 7: The Research Agenda